Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Medscape Education: Proud Friend of COA Sponsor at the Community Oncology Conference

April 25, 2025 | Advocate, COA2025, Empower, Oncology Education, Sponsor 

- PMLiVE

Medscape Education is honored to be a Friend of COA sponsor at the Community Oncology Conference, taking place from April 28-30th in Orlando, FL. This partnership highlights our commitment to advancing oncology education and improving patient care, aligning perfectly with this year’s theme: Empower & Advocate. 

With over 30 years of trusted learning, we deliver innovative, data-driven educational experiences that empower clinicians worldwide. Our unmatched reach ensures that oncologists and care teams can implement the latest advancements in practice. Notably, 79% of our US oncology physician learners are community practice-based oncologists, emphasizing our focus on this vital segment.

The Community Oncology Conference serves as a crucial platform for independent oncology professionals, uniting them to advocate for high-quality, affordable cancer care close to home. Together, we can shape the future of oncology education and ensure every patient receives the care they deserve.

For more information on Oncology Education, please contact Jelena Spyropoulos- PMLiVE

This content was provided by Medscape Education

Company Details

Medscape Logo

Medscape Education

Email
Website

 Latest Content from  Medscape Education 

Medscape Launches “Where Public Health Meets Practice” Learning Center to Translate Public Health Strategies into Patient Care

  The Medscape Division of Public Health announced the launch of the "Where Public Health Meets Practice" Learning Center, a dedicated educational destination on Medscape.org. The new center serves as...

Data, Evidence, Education: Tackling the Global Multi‑Trillion‑Dollar Rare Disease Burden

Rare diseases are individually uncommon, yet together they affect an estimated 300 million+ people worldwide and touch the lives of over one billion when families and caregivers are included. For...

#ShortenTheJourney

For the millions of people living with a rare disease, the path to a diagnosis (if ever received) is often a long and frustrating odyssey. This delay is frequently driven...

Why We Must Stop Normalizing the “Pregnancy Itch”

In the world of rare diseases, success is often measured by the speed of diagnosis. However, for women facing rare liver conditions like Intrahepatic Cholestasis of Pregnancy (ICP), the medical...

The Greatest Form of Caring: Medscape’s Commitment to Advancing Cardiovascular Health

A February Focus on the Heart  While February is known as the month of love, it is also National Heart Month, a time for highlighting the importance of cardiovascular health....

AI, Agility, and Connected Impact at Alliance 2026

Join the Medscape team in Atlanta, February 16–19, 2026, as Alliance celebrates 50 years of excellence in continuing education for health professionals. We’re bringing our 3 decades of experience in...

Why Sleep Health is the Missing Link in Women’s Wellness

While obstructive sleep apnea (OSA) affects approximately 32% of US adults—nearly 80 million people—it remains an "epidemic hiding in plain sight". Perhaps most staggering is that 90% of women with...

The Heart and Mouth Connection Every Woman Needs to Know

For decades, modern medicine has treated the mouth and the body as separate entities. But for Dr. Nieca Goldberg, a renowned cardiologist, and Dr. Maria Ryan, Chief Clinical Officer at...

Uncovering Inequities in Alzheimer’s Disease Screening and Care

  On December 5, MAPS hosted an educational webinar exploring recent research in Alzheimer’s disease (AD) screening, testing, and treatment. Experts from Komodo Health and Medscape shared findings from their...

Where Are We Today With Artificial Intelligence (AI) in Rare Disease Diagnosis and Care?

Discover how AI-powered tools are transforming rare disease diagnosis, patient care, and clinical decision-making.